Akero Therapeutics Inc. has released its financial results for the second quarter ending June 30, 2025. The company reported cash, cash equivalents, and short and long-term marketable securities amounting to $1,086.2 million. Akero expects these funds to support its current operating plan into 2028. Research and development expenses for the quarter were noted at $69.3 million, up from $55.3 million in the same period in 2024. This increase was primarily due to ongoing Phase 3 SYNCHRONY studies and the production of clinical supplies for Phase 3 and potential marketing applications, along with higher personnel costs. General and administrative expenses also rose to $11.6 million from $10.4 million in the previous year, driven by increased personnel and professional services expenses. The total operating expenses for the quarter were $80.9 million, compared to $65.7 million for the same period in 2024. Significant business updates include published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine and three presentations at the EASL Congress 2025. These presentations highlighted data showing statistically significant reversal of compensated cirrhosis (F4) due to MASH and confirmed the anti-fibrotic activity of EFX in patients with pre-cirrhotic (F2-F3) MASH. Additionally, AI-based analysis supported the treatment effect observed by conventional pathology scoring. A supporting poster suggested that qFibrosis® might detect fibrosis improvement earlier than conventional methods.